NBIX Stock Summary and Trading Ideas (Neurocrine Biosciences | NASDAQ:NBIX)

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences trades on the NASDAQ stock market under the symbol NBIX.

As of April 19, 2024, NBIX stock price declined to $132.00 with 491,239 million shares trading.

NBIX has a beta of 0.56, meaning it tends to be less sensitive to market movements. NBIX has a correlation of 0.10 to the broad based SPY ETF.

NBIX has a market cap of $13.13 billion. This is considered a Large Cap stock.

Last quarter Neurocrine Biosciences reported $515 million in Revenue and $1.54 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.39.

In the last 3 years, NBIX stock traded as high as $148.37 and as low as $71.88.

The top ETF exchange traded funds that NBIX belongs to (by Net Assets): VTI, IJH, VB, VXF, VBK.

NBIX has outperformed the market in the last year with a return of +27.3%, while the SPY ETF gained +21.2%. However, in the most recent history, NBIX shares have underperformed the stock market with its stock returning -3.5% in the last 3 month period and -4.1% for the last 2 week period, while SPY has returned +4.3% and -3.5%, respectively.

NBIX support price is $129.93 and resistance is $135.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NBIX stock will trade within this expected range on the day.